Evidence map›Paper›PMID 40240507›Full record

ArticleEye (London, England)2025

Drug-induced tubulointerstitial nephritis and uveitis syndrome in a nationwide surveillance.

Ayesh Ali, David G Downes, Taher K Eleiwa, Amr K Hassan, Reem H ElSheikh, Muhammad Z Chauhan, Lucia Ambrosio, Bharti R Nihalani, Paul H Phillips, Abdelrahman M Elhusseiny

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Eye (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ayesh AliDepartment of Rural Medicine, University of New England, Armidale, NSW, Australia.
David G DownesDepartment of Rural Medicine, University of New England, Armidale, NSW, Australia.
Taher K EleiwaDepartment of Ophthalmology, Benha University, Benha, Egypt.
Amr K HassanDepartment of Ophthalmology, University of California Irvine, Irvine, CA, USA.ORCID http://orcid.org/0000-0002-8281-9268
Reem H ElSheikhDepartment of Ophthalmology, Harvey and Bernice Jones Eye Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Muhammad Z ChauhanDepartment of Ophthalmology, Harvey and Bernice Jones Eye Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Lucia AmbrosioDepartment of Neuroscience, Reproductive and Odontostomatological Sciences, University of Naples Federico II, Naples, Italy.
Bharti R NihalaniDepartment of Ophthalmology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0001-9609-0546
Paul H PhillipsDepartment of Ophthalmology, Harvey and Bernice Jones Eye Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Abdelrahman M ElhusseinyDepartment of Ophthalmology, Harvey and Bernice Jones Eye Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA. AMElhusseiny@uams.edu.ORCID http://orcid.org/0000-0003-1412-375X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo investigate primary suspect drugs and identify a potential association between medication use and Tubulointerstitial Nephritis and Uveitis (TINU).

methodsA retrospective pharmacovigilance study was conducted using the Food and Drug Administration (FDA) Adverse Events Database (FAERS) from Q1 2004 to Q2 2024, focusing on patient demographics and statistical signal detection. A qualitative analysis assessed patient demographics. To ascertain if these reports yielded statistically significant signals, we used the proportional reporting ratio (PRR), chi-squared with Yates' correction (χ

resultsOne hundred twenty-six adverse reports for TINU were identified, along with 37 primary suspect drugs from the FAERS database. The mean age of patients was 30.05 ± 20.88 years. Most reports were of female patients (n = 67, 53%). Of the 37 primary suspect drugs, lamotrigine (n = 35, 27%) and diclofenac (n = 15, 12%) were the most frequently reported suspect drugs. The signal detection analysis also identified positive signals and potential causality for both drugs. Lamotrigine demonstrated the strongest positive signal (PRR = 90.09, χ2 = 3001.58, ROR 95% CI: 124.35 [84.20-183.66], EBGM [EBGM05]: 70.98 [50.21], IC [IC05]: 5.32 [4.83]), followed by diclofenac (PRR = 24.21, χ2 = 312.49, ROR 95% CI: 27.35 [15.95-46.90], EBGM [EBGM05]: 4.11 [2.47], IC [IC05]: 3.79 [2.99]).

conclusionOur study identified 37 primary suspect drugs associated with TINU, with lamotrigine and diclofenac showing the strongest statistical signals. Lamotrigine demonstrated the highest association, suggesting a potential drug-related risk for developing TINU, particularly in younger patients and females. Further research is warranted to explore causality and underlying mechanisms in these associations.

Indexed as

Drug-Related Side Effects and Adverse ReactionsNephritis, InterstitialUveitisAdolescentAdultAdverse Drug Reaction Reporting SystemsAgedChildChild, PreschoolDatabases, FactualFemaleHumansMaleMiddle AgedPharmacovigilanceRetrospective Studies

Identifiers

PMID40240507
PMCPMC12209433

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.